Phase II study to investigate the efficacy and safety of ZK 219477 [sagopilone] as first line therapy in chemotherapy naive patients with extensive disease (ED) stage small cell lung cancer (SCLC).

Trial Profile

Phase II study to investigate the efficacy and safety of ZK 219477 [sagopilone] as first line therapy in chemotherapy naive patients with extensive disease (ED) stage small cell lung cancer (SCLC).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 26 Jan 2016

At a glance

  • Drugs Sagopilone (Primary)
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Bayer
  • Most Recent Events

    • 30 Dec 2015 Status changed from completed to discontinued as per ClinicalTrials.gov record.
    • 12 Jul 2011 New source identified and integrated (European Clinical Trials Database; EudraCT2005-000597-53).
    • 12 May 2009 Company added as trial sponsor and affiliate as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top